Press Releases

11.07.2017

Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

11.01.2017

Encycle Therapeutics announces discovery collaboration with Pfizer Inc.

10.31.2017

Pfizer Reports Third-Quarter 2017 Results

10.29.2017

One Year Maintenance and Switching Data in Patients with Crohn’s Disease Support the Use of INFLECTRA®* (infliximab CT-P13) in IBD1

10.16.2017

New Ulcerative Colitis Data for XELJANZ® (tofacitinib) at Upcoming Gastroenterology Congresses

10.16.2017

Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

10.13.2017

The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries to address the needs of metastatic breast cancer patients worldwide

10.12.2017

U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV

10.10.2017

Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business

10.05.2017

Pfizer Launches Novel Programs to Put Important Support Services at the Fingertips of Cancer Patients

10.04.2017

AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program

09.27.2017

Pfizer Declares 32-Cent Fourth-Quarter 2017 Dividend